CN116042688B - Highly saturated transposon mutant library and construction method of X. citri - Google Patents
Highly saturated transposon mutant library and construction method of X. citri Download PDFInfo
- Publication number
- CN116042688B CN116042688B CN202310200163.3A CN202310200163A CN116042688B CN 116042688 B CN116042688 B CN 116042688B CN 202310200163 A CN202310200163 A CN 202310200163A CN 116042688 B CN116042688 B CN 116042688B
- Authority
- CN
- China
- Prior art keywords
- trans
- transposon
- pln2
- xanthomonas
- plln2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010276 construction Methods 0.000 title claims abstract description 17
- 241000589655 Xanthomonas citri Species 0.000 title claims description 15
- 229920006395 saturated elastomer Polymers 0.000 title claims description 13
- 241000589634 Xanthomonas Species 0.000 claims abstract description 40
- 239000013612 plasmid Substances 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 28
- 238000003780 insertion Methods 0.000 claims description 26
- 230000037431 insertion Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 238000012163 sequencing technique Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 229930027917 kanamycin Natural products 0.000 claims description 11
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 11
- 229960000318 kanamycin Drugs 0.000 claims description 11
- 229930182823 kanamycin A Natural products 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 102000008579 Transposases Human genes 0.000 claims description 6
- 108010020764 Transposases Proteins 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 238000007852 inverse PCR Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000003672 processing method Methods 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 102000004533 Endonucleases Human genes 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 abstract description 36
- 241000207199 Citrus Species 0.000 abstract description 7
- 235000020971 citrus fruits Nutrition 0.000 abstract description 6
- 230000003321 amplification Effects 0.000 abstract description 5
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 5
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 4
- 241000589495 Xanthobacter flavus Species 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000009826 distribution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000010436 membrane biogenesis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150023648 pcaF gene Proteins 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/64—Xanthomonas
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域technical field
本发明涉及生物产业技术领域,具体涉及柑橘溃疡病菌高饱和转座子突变体库及构建方法。The invention relates to the technical field of biological industry, in particular to a highly saturated transposon mutant library of X. citri and a construction method thereof.
背景技术Background technique
柑橘溃疡病是一种严重威胁柑橘种产量和质量的植物病害,其是由柑橘黄单胞菌柑橘亚种引起的细菌性病害,柑橘溃疡病发病轻则造成柑橘果实、叶片带有病疤;重则造成果实落果,幼树落叶,导致农民减收。Citrus canker is a plant disease that seriously threatens the yield and quality of citrus species. It is a bacterial disease caused by Xanthomonas citri subsp. If it is serious, it will cause the fruit to drop and the young trees to lose their leaves, resulting in a reduction in farmers' income.
黄单胞菌通过柑橘叶片或果实表面的气孔或伤口侵入,在侵染成功并大量繁殖后借助喷发性脓疱向外逸散,从而开始下一轮侵染周期。目前对于柑橘溃疡病的防治尚未有完善的方法,生产中一般通过喷施铜制剂或砍除病树进行病害防控,但产生环境及抗药性问题。本发明利用转座子突变结合高通量测序技术鉴定柑橘溃疡病菌必需基因,有望为病害防治发掘新的药物靶标。Xanthomonas invades through stomata or wounds on the surface of citrus leaves or fruits. After successful infection and massive reproduction, it escapes outwards through eruptive pustules, thus starting the next round of infection cycle. At present, there is no perfect method for the prevention and treatment of citrus canker. In production, the disease is generally prevented and controlled by spraying copper preparations or cutting down diseased trees, but environmental and drug resistance problems arise. The invention uses transposon mutation combined with high-throughput sequencing technology to identify essential genes of X. citri, which is expected to discover new drug targets for disease prevention and control.
发明内容Contents of the invention
本发明针对上述问题,提供了柑橘溃疡病菌高饱和转座子突变体库及构建方法,具体通过构建柑橘溃疡病菌高饱和转座子突变体库并运用高通量测序技术鉴定其必需基因的方法,用于柑橘黄单胞菌柑橘亚种引起的细菌性柑橘溃疡病的研究与防治。本发明实现了高效的扩增转座子及其侧翼区域的扩增,从而大大降低了制备测序文库的成本,同时由于反向PCR扩增片段可由PCR程序决定,侧翼序列也较长,比对结果更准确。In view of the above problems, the present invention provides a highly saturated transposon mutant library of X. citri and a construction method thereof, specifically by constructing a highly saturated transposon mutant library of X. citri and using high-throughput sequencing technology to identify its essential genes , for the research and control of bacterial citrus canker caused by Xanthomonas citri subsp. The invention realizes efficient amplification of transposons and their flanking regions, thereby greatly reducing the cost of preparing sequencing libraries. At the same time, because the reverse PCR amplification fragment can be determined by the PCR program, the flanking sequences are also relatively long, and the comparison The result is more accurate.
本发明的技术方案如下:Technical scheme of the present invention is as follows:
柑橘溃疡病菌高饱和转座子突变体库的构建方法,步骤如下:A method for constructing a highly saturated transposon mutant library of X. citri, the steps are as follows:
S1:质粒pLN2-Trans和pLLN2-Trans的构建:S1: Construction of plasmids pLN2-Trans and pLLN2-Trans:
(1)构建pLN2-Trans,在pN2-Trans中转座酶内连接乳糖启动子Plac获得pLN2-Trans;(1) Construct pLN2-Trans, and connect the lactose promoter Plac to pN2-Trans to obtain pLN2-Trans;
优选的,使用引物扩增pBBR1MCS-2载体中LacZ基因上游270bp的核苷酸序列,获得驱动基因表达的乳糖启动子;使用无缝克隆组装法将乳糖启动子替换已知载体pMCS2-transposase中的转座酶自身启动子片段,得到用于构建转座子插入突变体库的载体pLN2-Trans;Preferably, primers are used to amplify the 270 bp nucleotide sequence upstream of the LacZ gene in the pBBR1MCS-2 vector to obtain a lactose promoter that drives gene expression; the lactose promoter is replaced by the lactose promoter in the known vector pMCS2-transposase using the seamless cloning assembly method The promoter fragment of the transposase itself is obtained to obtain the vector pLN2-Trans for constructing the transposon insertion mutant library;
(2)构建pLLN2-Trans,在步骤(1)获得的pLN2-Trans中的转座酶5’端连接Plac;(2) Construct pLLN2-Trans, and connect Plac at the 5' end of the transposase in pLN2-Trans obtained in step (1);
优选的,使用NdeI 和KpnI双酶切处理pLN2-Trans获得线性化载体;使用引物扩增pBBR1MCS-2载体中LacZ基因上游270bp的核苷酸序列;使用无缝克隆组装法将启动子片段连接至线性化的载体中,获得用于构建转座子插入突变体库的载体pLLN2-Trans。Preferably, use NdeI and KpnI double digestion to treat pLN2-Trans to obtain a linearized vector; use primers to amplify the 270bp nucleotide sequence upstream of the LacZ gene in the pBBR1MCS-2 vector; use the seamless cloning assembly method to connect the promoter fragment to Among the linearized vectors, the vector pLLN2-Trans used to construct the transposon insertion mutant library was obtained.
S2:基于质粒pLN2-Trans和pLLN2-Trans的转座子突变体文库的构建方法,步骤如下:S2: A method for constructing a transposon mutant library based on plasmids pLN2-Trans and pLLN2-Trans, the steps are as follows:
(1)制备黄单胞菌感受态细胞;(1) Prepare Xanthomonas competent cells;
优选的,准备单菌落培养获得的黄单胞菌菌液,离心后使用无菌水重悬。使用预冷的10 %甘油多次洗涤细胞获得黄单胞菌感受态细胞。Preferably, the Xanthomonas bacteria liquid obtained by single colony culture is prepared and resuspended with sterile water after centrifugation. Cells were washed several times with pre-cooled 10% glycerol to obtain Xanthomonas competent cells.
(2)将步骤(1)获得黄单胞菌感受态细胞分别加入到质粒pLN2-Trans和pLLN2-Trans中混合,体积均为90:2,通过电击将质粒导入黄单胞菌中;使用额外添加了质量分数为1 %蔗糖的NB液体培养基培育,使用添加50 μg/ml 卡那霉素的NB固体培养基筛选,分别获得转座子pLN2-Trans和pLLN2-Trans成功转化的黄单胞菌;(2) Add the Xanthomonas competent cells obtained in step (1) to the plasmids pLN2-Trans and pLLN2-Trans and mix, both volumes are 90:2, and introduce the plasmids into Xanthomonas by electric shock; use additional The NB liquid medium with a mass fraction of 1% sucrose was added, and the NB solid medium supplemented with 50 μg/ml kanamycin was selected to obtain xanthomonads successfully transformed by the transposon pLN2-Trans and pLLN2-Trans, respectively bacteria;
优选的,将步骤(1)获得黄单胞菌感受态细胞分别加入到质粒pLN2-Trans和pLLN2-Trans中混合后,通过30次电击将转座子载体导入黄单胞菌中;使用添加质量分数为1 %蔗糖的NB液体培养基培育,静置于30 ℃培养箱孵育3 h;随后铺板于添加50 μg/ml 卡那霉素的NB固体培养基上,30℃倒置培养2 d;分别获得转座子pLN2-Trans和pLLN2-Trans成功转化的黄单胞菌。Preferably, the Xanthomonas competent cells obtained in step (1) are added to the plasmids pLN2-Trans and pLLN2-Trans and mixed, and the transposon vector is introduced into Xanthomonas by 30 electric shocks; The NB liquid medium with a fraction of 1% sucrose was cultivated, and incubated in a 30°C incubator for 3 h; then plated on the NB solid medium supplemented with 50 μg/ml kanamycin, and cultured upside down at 30°C for 2 d; Xanthomonas successfully transformed with transposons pLN2-Trans and pLLN2-Trans were obtained.
(3)将步骤(2)获得的转座子pLN2-Trans成功转化的黄单胞菌和转座子pLLN2-Trans成功转化的黄单胞菌分别刮板,然后分别将获得的黄单胞菌体加入到添加50 μg/ml卡那霉素的NB液体培养基中,分别获得转化pLN2-Trans和pLLN2-Trans的突变体库,分别命名为T1和T2。将突变体文库均匀分装后全部保存于-80 ℃冷藏。(3) Scrape the Xanthomonas successfully transformed with the transposon pLN2-Trans obtained in step (2) and the Xanthomonas successfully transformed with the transposon pLLN2-Trans respectively, and then separate the obtained Xanthomonas The mutants were added to NB liquid medium supplemented with 50 μg/ml kanamycin to obtain mutant libraries transformed into pLN2-Trans and pLLN2-Trans, which were named T1 and T2, respectively. The mutant library was evenly divided and stored at -80°C.
本发明还包括通过上述构建方法获得的柑橘溃疡病菌高饱和转座子突变体库。The present invention also includes the highly saturated transposon mutant library of X. citri obtained by the above construction method.
进一步的,本发明还包括了测序文库及制备方法,步骤如下:Further, the present invention also includes a sequencing library and a preparation method, the steps are as follows:
对突变体文库用添加50 μg/ml 卡那霉素的NB液体培养基进行扩大培养,使用CTAB法提取黄单胞菌基因组DNA,使用限制性内切酶NcoⅠ、EcoRI、BamHI、SphI、MfeI、MluI、NotI消化处理基因组DNA,用100 %乙醇重新沉淀提取DNA,然后加入T4连接酶自连,使用胶回收试剂盒进行DNA纯化后,使用限制酶特异性引物进行反向PCR, PCR的条件为:98℃3min,98℃ 10s,58℃ 15s,72℃ 2 min,33个循环,72℃ 10 min,12℃保温,获得载体转座子侧翼基因组序列片段;随后再次使用胶回收试剂盒进行DNA纯化,即得到测序文库。The mutant library was expanded with NB liquid medium supplemented with 50 μg/ml kanamycin, and the genomic DNA of Xanthomonas was extracted using the CTAB method, and the restriction enzymes NcoI, EcoRI, BamHI, SphI, MfeI, Genomic DNA was digested with MluI and NotI, reprecipitated with 100% ethanol to extract the DNA, and then added T4 ligase for self-ligation. After DNA purification was performed using a gel recovery kit, reverse PCR was performed using restriction enzyme specific primers. The conditions for PCR were: : 98°C for 3 minutes, 98°C for 10s, 58°C for 15s, 72°C for 2 minutes, 33 cycles, 72°C for 10 minutes, and incubation at 12°C to obtain vector transposon flanking genome sequence fragments; then use the gel recovery kit again for DNA Purify to obtain the sequencing library.
进一步的,所述测序文库的数据处理方法,所述方法如下:Further, the data processing method of the sequencing library, the method is as follows:
在window10系统电脑中安装Ubuntu,构建Linux子系统。使用fastp软件对原始测序数据进行质控,使用seqkit软件去重复序列,并以载体转座子末端序列进行单向特异性筛选。通过要求25 bp O-end端序列或I-end端序列完全匹配,筛选获得T1读出序列。分别进行正向和反向筛选后,将反向序列颠倒后合并。使用基于bwa的TPP软件识别O-end端序列,将结果映射到黄单胞菌全基因组(CQ13菌株染色体基因组及其2个质粒)上,得到插入位点。对插入位点的数据提取后进行筛选以删除测序的序列和基因组序列不完全匹配的情况,提取有效数据进行后续分析。Install Ubuntu on a Windows 10 system computer to build a Linux subsystem. The quality control of the original sequencing data was carried out by using fastp software, and the repeated sequence was removed by seqkit software, and the one-way specificity screening was carried out with the end sequence of the vector transposon. T1 reads were screened by requiring a 25 bp O-end sequence or I-end sequence exact match. After performing forward and reverse screening respectively, the reverse sequence was reversed and merged. The O-end sequence was identified using the bwa-based TPP software, and the results were mapped to the whole genome of Xanthomonas (CQ13 strain chromosomal genome and its two plasmids) to obtain the insertion site. After the data of the insertion site is extracted, screening is performed to delete the incomplete match between the sequenced sequence and the genome sequence, and effective data is extracted for subsequent analysis.
本发明与现有技术相比具有以下优点:Compared with the prior art, the present invention has the following advantages:
(1)本发明采用的T1转座子则实现了对全基因组超过70万随机位点的突变,建立了分辨率可达到8 bp的高饱和突变体库。(1) The T1 transposon used in the present invention realizes the mutation of more than 700,000 random sites in the whole genome, and establishes a highly saturated mutant library with a resolution of 8 bp.
(2)本发明通过反向PCR和多种酶切结合的方式实现了高效的扩增转座子和扩增其侧翼区域,从而大大降低了制备测序文库的成本,同时由于反向PCR扩增片段可由PCR程序决定,侧翼序列也较长,比对结果更准确。(2) The present invention achieves efficient amplification of transposons and amplification of their flanking regions through the combination of inverse PCR and various enzyme cuts, thereby greatly reducing the cost of preparing sequencing libraries, and at the same time due to inverse PCR amplification The fragment can be determined by the PCR program, and the flanking sequence is also longer, so the comparison result is more accurate.
附图说明Description of drawings
图1为pLN2-Trans和pLLN2-Trans质粒在全基因组上转座子在各个基因上插入分布的极性效应图;Figure 1 is a graph showing the polarity effect of transposon insertion distribution on each gene of pLN2-Trans and pLLN2-Trans plasmids in the whole genome;
图2为pLN2-Trans和pLLN2-Trans在各个基因上插入差异的极性效应图;Figure 2 is a graph showing the polarity effect of insertion differences between pLN2-Trans and pLLN2-Trans in each gene;
图3为操纵子的转座子插入情况的极性效应图;Fig. 3 is a diagram of the polarity effect of the transposon insertion of the operon;
图4为基于COG功能类的必需基因组中的各类别聚类研究图;Figure 4 is a clustering study diagram of each category in the essential genome based on the COG functional class;
图5为COG分类的富集图;Figure 5 is an enrichment map of COG classification;
图6为基于KEGG的必需基因组聚类研究;Figure 6 is a KEGG-based essential genome clustering study;
图7为必需基因在全基因组上的分布。Figure 7 shows the distribution of essential genes on the whole genome.
具体实施方式Detailed ways
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。The present invention will be further described below in conjunction with specific embodiments, and the advantages and characteristics of the present invention will become clearer along with the description. However, the examples are merely exemplary and do not limit the scope of the present invention in any way. Those skilled in the art should understand that the details and forms of the technical solutions of the present invention can be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention.
实施例1:柑橘溃疡病菌高饱和转座子突变体库及构建方法Example 1: X. citri highly saturated transposon mutant library and construction method
构建步骤如下:The build steps are as follows:
S1:质粒pLN2-Trans和pLLN2-Trans的构建:S1: Construction of plasmids pLN2-Trans and pLLN2-Trans:
(1)使用引物扩增pBBR1MCS-2载体中LacZ基因上游270bp的核苷酸序列,获得驱动基因表达的乳糖启动子;使用无缝克隆组装法将乳糖启动子替换已知载体pMCS2-transposase中的转座酶自身启动子片段,得到用于构建转座子插入突变体库的载体pLN2-Trans;(1) Use primers to amplify the 270 bp nucleotide sequence upstream of the LacZ gene in the pBBR1MCS-2 vector to obtain the lactose promoter driving gene expression; use the seamless cloning assembly method to replace the lactose promoter in the known vector pMCS2-transposase The promoter fragment of the transposase itself is obtained to obtain the vector pLN2-Trans for constructing the transposon insertion mutant library;
(2)构建pLLN2-Trans,使用NdeI 和KpnI双酶切处理pLN2-Trans获得线性化载体;使用引物扩增pBBR1MCS-2载体中LacZ基因上游270bp的核苷酸序列;使用无缝克隆组装法将启动子片段连接至线性化的载体中,获得用于构建转座子插入突变体库的载体pLLN2-Trans。(2) Construct pLLN2-Trans, and use NdeI and KpnI double digestion to treat pLN2-Trans to obtain a linearized vector; use primers to amplify the 270bp nucleotide sequence upstream of the LacZ gene in the pBBR1MCS-2 vector; use the seamless cloning assembly method to The promoter fragment was ligated into the linearized vector to obtain the vector pLLN2-Trans for constructing the transposon insertion mutant library.
S2:基于质粒pLN2-Trans和pLLN2-Trans的转座子突变体文库的构建S2: Construction of transposon mutant libraries based on plasmids pLN2-Trans and pLLN2-Trans
构建步骤如下:The build steps are as follows:
(1)制备黄单胞菌感受态细胞,准备300 ml单菌落培养获得的黄单胞菌菌液,离心后使用6 ml无菌水重悬。使用预冷的10 %甘油多次洗涤细胞获得黄单胞菌感受态细胞;(1) To prepare Xanthomonas competent cells, prepare 300 ml of Xanthomonas bacterial liquid obtained from single colony culture, resuspend in 6 ml of sterile water after centrifugation. Use pre-cooled 10% glycerol to wash the cells several times to obtain Xanthomonas competent cells;
(2)将步骤(1)获得黄单胞菌感受态细胞分别加入到质粒pLN2-Trans和pLLN2-Trans中混合,体积均为90:2,通过30次电击将转座子载体导入黄单胞菌中;使用添加质量分数为1 %蔗糖的NB液体培养基培育,静置于30 ℃培养箱孵育3 h;随后铺板于添加50 μg/ml 卡那霉素的NB固体培养基上,30℃倒置培养2 d,分别获得转座子pLN2-Trans和pLLN2-Trans成功转化的黄单胞菌;(2) Add the Xanthomonas competent cells obtained in step (1) to the plasmids pLN2-Trans and pLLN2-Trans and mix, the volume is 90:2, and the transposon vector is introduced into Xanthomonas by 30 electric shocks Bacteria; cultured in NB liquid medium with 1% sucrose added, and incubated in a 30°C incubator for 3 h; then plated on NB solid medium added with 50 μg/ml kanamycin at 30°C Xanthomonas successfully transformed by transposon pLN2-Trans and pLLN2-Trans were obtained by inverting culture for 2 days;
(3)将步骤(2)获得的转座子pLN2-Trans成功转化的黄单胞菌和转座子pLLN2-Trans成功转化的黄单胞菌分别刮板加入添加50 μg/ml 卡那霉素的NB液体培养基中,分别获得转化pLN2-Trans和pLLN2-Trans的突变体库,分别命名为T1和T2。将突变体文库均匀分装后全部保存于-80 ℃冷藏。(3) Add 50 μg/ml kanamycin to the Xanthomonas successfully transformed by the transposon pLN2-Trans obtained in step (2) and the Xanthomonas successfully transformed by the transposon pLLN2-Trans respectively In the NB liquid culture medium, the mutant libraries transformed into pLN2-Trans and pLLN2-Trans were obtained, respectively named as T1 and T2. The mutant library was evenly divided and stored at -80°C.
实施例2:TnSeq测序文库及制备方法Embodiment 2: TnSeq sequencing library and preparation method
步骤如下:Proceed as follows:
对突变体文库T1和T2用100 ml添加50 μg/ml 卡那霉素的NB液体培养基进行扩大培养,使用CTAB法提取黄单胞菌基因组DNA,使用限制性内切酶NcoⅠ、EcoRI、BamHI、SphI、MfeI、MluI、NotI消化处理基因组DNA,用100%乙醇重新沉淀提取DNA,然后加入T4连接酶自连,使用胶回收试剂盒(omega)进行DNA纯化后;使用胶回收试剂盒进行DNA纯化后,使用限制酶特异性引物进行反向PCR,PCR的条件为:98℃ 3min,98℃ 10s,58℃ 15s,72℃ 2 min,33个循环,72℃ 10 min,12℃保温,获得载体转座子侧翼基因组序列片段;随后再次使用胶回收试剂盒(Omega)进行DNA纯化,即得TnSeq测序文库。The mutant library T1 and T2 were expanded with 100 ml of NB liquid medium supplemented with 50 μg/ml kanamycin, and the genomic DNA of Xanthomonas was extracted using the CTAB method, and the restriction enzymes NcoI, EcoRI, BamHI , SphI, MfeI, MluI, and NotI to digest and process genomic DNA, reprecipitate and extract DNA with 100% ethanol, then add T4 ligase for self-ligation, use gel recovery kit (omega) for DNA purification; use gel recovery kit for DNA After purification, reverse PCR was performed using restriction enzyme specific primers. The PCR conditions were: 98°C for 3 min, 98°C for 10 s, 58°C for 15 s, 72°C for 2 min, 33 cycles, 72°C for 10 min, and incubation at 12°C to obtain Carrier transposon flanking genome sequence fragments; followed by DNA purification using the gel recovery kit (Omega) again to obtain a TnSeq sequencing library.
所述TnSeq测序文库的数据处理方法,所述方法如下:The data processing method of described TnSeq sequencing library, described method is as follows:
在window10系统电脑中安装Ubuntu,构建Linux子系统。使用fastp软件对原始测序数据进行质控,使用seqkit软件去重复,并以载体转座子末端序列进行单向特异性筛选。通过要求25 bp O-end端序列或I-end端序列完全匹配,筛选获得T1读出序列。分别进行正向和反向筛选后,将反向序列颠倒后合并。使用基于bwa的TPP软件识别O-end端序列,将结果映射到黄单胞菌全基因组(CQ13菌株染色体基因组及其2个质粒)上,得到插入位点。对插入位点的数据提取后进行筛选以删除不完全匹配的情况,提取有效数据进行后续分析。Install Ubuntu on a
试验例:Test example:
1.高饱和插入突变体库的建立1. Establishment of highly saturated insertion mutant library
通过实施例1,使用pLN2-Trans质粒转化收集到了400000左右的突变体单菌落,构建了转座子突变文库T1;使用pLLN2-Trans质粒转化收集到大约500000的突变体单菌落,构建了转座子突变文库T2。According to Example 1, about 400,000 mutant single colonies were collected by pLN2-Trans plasmid transformation, and the transposon mutation library T1 was constructed; about 500,000 mutant single colonies were collected by pLLN2-Trans plasmid transformation, and transposition was constructed. Submutation library T2.
将两次得到的突变体文库T1和T2汇总后分别培养、提取基因组DNA、酶切消化基因组DNA、反向PCR建库。高通量测序共得到了123958517条测序序列,映射到基因组上得到了737899个独立插入位点,该数据表明插入丰度达到了每8个bp单个插入的高饱和分辨率。The mutant libraries T1 and T2 obtained twice were pooled and cultured respectively, genomic DNA was extracted, genomic DNA was digested with restriction enzymes, and the library was constructed by inverse PCR. A total of 123,958,517 sequencing sequences were obtained by high-throughput sequencing, and 737,899 independent insertion sites were obtained by mapping to the genome. This data shows that the insertion abundance has reached a high saturation resolution of a single insertion per 8 bp.
必需基因的鉴定Identification of essential genes
必需基因指在某些条件下,对维持生命体正常生存不可缺少的基因。不同的物种具有不同的基因组大小和基因组成,但是这些差别很大的基因组都包含一套必需基因用以维持关键的细胞功能。必需基因大多数是该种生命体中负责 DNA 复制、转录、翻译及蛋白质折叠等不可或缺的生命反应的管家基因,它揭示了一个物种最基础的生物机制,对于必需基因的深入有助于人们理解生命的起源以及在进化过程中不同物种之间的联系。Essential genes refer to genes that are indispensable to maintain the normal survival of living organisms under certain conditions. Different species have different genome sizes and genetic compositions, but these vastly different genomes all contain a set of essential genes for key cellular functions. Most of the essential genes are housekeeping genes responsible for the indispensable life reactions of DNA replication, transcription, translation, and protein folding in this kind of life. People understand the origin of life and the connections between different species during evolution.
使用TRANSIT中的Tn5Gaps来对所有的基因进行必要性鉴定。通过Tn5Gaps计算得到的p值(p value<0.05),共筛选到525个必需基因和181个高适合度基因,其中必需基因中包含48个功能未知蛋白。Essentiality identification of all genes was performed using Tn5Gaps in TRANSIT. According to the p value calculated by Tn5Gaps (p value<0.05), a total of 525 essential genes and 181 high-fitness genes were screened, and 48 proteins with unknown functions were included in the essential genes.
极性效应对操纵子内部相邻基因的影响Polarity effects on adjacent genes within an operon
通过对突变体库T1与T2的比较,统计了转座子在全基因组上所有基因的分布,并计算在单个基因上插入的转座子数量与在所有基因中的转座子数量的比率和两者之间的差距,其中基因XCQ_RS1890属于必需基因,而该基因上游的基因XCQ_RS1885和下游的pcaF是非必需基因;其结果如图1和图2所示,T1和T2的插入在全基因组上的趋势是相似的,这也与文献中所说极性效应仅在少部分情况下对临近基因产生影响的结论相吻合。图2中若T1插入丰度大于T2,两者差值为正;若T1插入丰度小于T2,两者差值为负。By comparing the mutant library T1 and T2, the distribution of transposons in all genes on the whole genome was counted, and the ratio of the number of transposons inserted in a single gene to the number of transposons in all genes was calculated and The gap between the two, the gene XCQ_RS1890 is an essential gene, and the gene XCQ_RS1885 upstream of the gene and pcaF downstream are non-essential genes; the results are shown in Figure 1 and Figure 2, the insertion of T1 and T2 in the whole genome The trend is similar, which is also consistent with the conclusion that the polarity effect only affects adjacent genes in a small number of cases in the literature. In Figure 2, if the insertion abundance of T1 is greater than T2, the difference between the two is positive; if the insertion abundance of T1 is less than T2, the difference between the two is negative.
统计了在同一个操纵子内的必需基因上游的非必需基因在T1和T2的插入情况,并重点关注在T1情况下没有插入的非必需基因,共统计了86个非必需基因,并获得了28个在T1条件下没有插入的非必需基因,其中有25个基因在T2条件下表现为容忍转座子插入,如图3展示的一个操纵子中,其中必需基因XCQ_RS1890上游的非必需基因在T1中未被转座子插入,但在T2中则容许转座子插入,且其下游的转座子插入没有受到明显影响。该数据表明pLN2-Trans中外向的启动子有效地减少了极性效应对必需基因周围非必需基因的影响,提高了对必需基因鉴定的准确率。Counting the insertion of non-essential genes upstream of essential genes in the same operon in T1 and T2, and focusing on non-essential genes that are not inserted in T1, a total of 86 non-essential genes were counted, and obtained Of the 28 non-essential genes that were not inserted under T1 conditions, 25 of them were shown to tolerate transposon insertions under T2 conditions, as shown in Figure 3 in an operon, where the non-essential gene upstream of the essential gene XCQ_RS1890 is in T1 was not inserted by transposons, but transposon insertions were allowed in T2, and the downstream transposon insertions were not significantly affected. The data indicated that the outward-facing promoter in pLN2-Trans effectively reduced the impact of polarity effects on non-essential genes around essential genes, and improved the accuracy of identification of essential genes.
必需基因的功能特征Functional characterization of essential genes
对黄单胞菌的必需基因组通过COG(Cluster of Orthologous Groups)或者KEGG进行功能分类,COG(如图4,条形图旁边是基因的数量)展示了约有三分之一的必需基因集中在三个功能分类中:15%的基因与基因翻译、核糖体结构和生物学合成有关(J)、9.3%的基因与能量生产和转换相关(C)、7.6%的则与细胞壁/细胞膜的生物学合成相关(M)。虽然不同的黄单胞菌必需基因组的富集程度不同,但是其富集趋势却是相似的:必需基因多集中于翻译、能量代谢等基础功能。分析展示了62个功能未知的必需基因。而另一种COG分析展示了在全基因组中不同功能分类的丰富程度如图5所示,对功能重要性做了更准确的评估,计算方法为必需基因组中某一特定基因类与其在基因组中总比例的比例。评估显示了必需基因富集聚类类别:基因翻译、核糖体结构和生物学合成(J)、核苷酸转运和代谢(F)、辅酶转运和代谢(H)、能量生产和转换(C)、细胞周期控制,细胞分裂和染色体分配(D)、细胞内运输、分泌和囊泡运输(U)、DNA复制重组和修复(L)、细胞膜生物发生(M)和翻译后修饰、蛋白质周转和分子伴侣等(O)。The essential genomes of Xanthomonas are functionally classified by COG (Cluster of Orthologous Groups) or KEGG. COG (as shown in Figure 4, the number of genes next to the bar graph) shows that about one-third of the essential genes are concentrated in Among the three functional categories: 15% of the genes are related to gene translation, ribosome structure and biological synthesis (J), 9.3% of the genes are related to energy production and conversion (C), 7.6% are related to the biology of the cell wall/cell membrane Learning Synthetic Correlation (M). Although the enrichment levels of the essential genomes of different Xanthomonas were different, their enrichment trends were similar: the essential genes were mostly concentrated in basic functions such as translation and energy metabolism. The analysis revealed 62 essential genes of unknown function. Another COG analysis shows the richness of different functional categories in the whole genome, as shown in Figure 5, which makes a more accurate assessment of the importance of functions, and the calculation method is the relationship between a specific gene class in the essential genome and its presence in the genome. The proportion of the total proportion. Assessment showing essential gene enrichment cluster categories: Gene Translation, Ribosome Structure and Biological Synthesis (J), Nucleotide Transport and Metabolism (F), Coenzyme Transport and Metabolism (H), Energy Production and Conversion (C) , cell cycle control, cell division and chromosome allocation (D), intracellular trafficking, secretion and vesicular trafficking (U), DNA replication recombination and repair (L), cell membrane biogenesis (M) and post-translational modifications, protein turnover and Molecular chaperones, etc. (O).
除了COG外,还使用了KEGG途径对基因组功能进行了更为详细的聚类,如图6所示。在图中显示了tRNA-氨基酸转运、核糖体和光合作用相关的必需基因数量明显多于其他,同时tRNA-氨基酸转运、细胞周期相关基因中必需基因占比也远高于其他功能(分别为87.5%和88.3%)。In addition to COG, a more detailed clustering of genomic functions was performed using the KEGG pathway, as shown in Figure 6. The figure shows that the number of essential genes related to tRNA-amino acid transport, ribosome and photosynthesis is significantly more than others, and the proportion of essential genes in tRNA-amino acid transport and cell cycle-related genes is also much higher than that of other functions (respectively 87.5 % and 88.3%).
必需基因在全基因组上的分布和比较Genome-wide distribution and comparison of essential genes
对柑橘溃疡病菌中的必需基因在全基因组上的分布进行分析和作图,以500000bp碱基为移动窗口,10000碱基为步移距离,用超几何分布计算在该窗口内必需基因出现的概率并指定p值,对全基因组上的p值处理后作图,如图7所示。Analyze and map the distribution of essential genes in X. citri on the whole genome. With 500,000 bases as the moving window and 10,000 bases as the step distance, the hypergeometric distribution is used to calculate the probability of essential genes appearing in this window And specify the p value, and plot the p value on the whole genome after processing, as shown in Figure 7.
图7展示了在全基因组范围内必需基因的富集程度,在全基因组约0.2处(1000000碱基处)必需基因富集程度达到最高值,经过检查,发现这里是核糖体结构编码蛋白的集中区域,除此以外,还发现柑橘溃疡病菌染色体DNA复制起始位点和末端位点的富集程度不足,这点与熟知的另外两种细菌均有所差异:新月柄杆菌的必需基因多集中在中央和起始末端区域,大肠杆菌则是在临近起始位点区域有更高的必需基因富集。Figure 7 shows the enrichment of essential genes in the whole genome. The enrichment of essential genes reaches the highest value at about 0.2 (1,000,000 bases) in the whole genome. After inspection, it is found that this is the concentration of proteins encoded by the ribosome structure In addition, it was also found that the enrichment of the chromosomal DNA replication start site and terminal site of X. Concentrated in the central and start-end regions, E. coli had a higher enrichment of essential genes in the region near the start site.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310200163.3A CN116042688B (en) | 2023-03-06 | 2023-03-06 | Highly saturated transposon mutant library and construction method of X. citri |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310200163.3A CN116042688B (en) | 2023-03-06 | 2023-03-06 | Highly saturated transposon mutant library and construction method of X. citri |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116042688A CN116042688A (en) | 2023-05-02 |
CN116042688B true CN116042688B (en) | 2023-06-20 |
Family
ID=86127530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310200163.3A Active CN116042688B (en) | 2023-03-06 | 2023-03-06 | Highly saturated transposon mutant library and construction method of X. citri |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116042688B (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000916A2 (en) * | 2000-06-28 | 2002-01-03 | California Institute Of Technology | Methods for identifying an essential gene in a prokaryotic microorganism |
CN101260399A (en) * | 2008-03-13 | 2008-09-10 | 邓子牛 | Anti-citrus canker pthA-nls gene and its construction method and application |
WO2011109031A1 (en) * | 2010-03-05 | 2011-09-09 | Synthetic Genomics, Inc. | Methods for cloning and manipulating genomes |
GB201322084D0 (en) * | 2013-12-13 | 2014-01-29 | Discuva Ltd | Method for identifying genes involved in antibiotic resistance and sensitivity in gram-negative bacteria |
CN106086070A (en) * | 2016-06-07 | 2016-11-09 | 中山大学 | A kind of ProtoRAG Transposon System and application thereof |
WO2016180379A1 (en) * | 2015-05-14 | 2016-11-17 | Universidad De Los Andes | Novel transposon that promotes the functional expression of genes in episomal dna, and method for increasing dna transcription in the functional analysis of metagenomic libraries |
CN106754606A (en) * | 2017-01-11 | 2017-05-31 | 中国农业科学院柑桔研究所 | The screening technique of the unmarked deletion mutant of citrus processing hfq genes |
CN106916774A (en) * | 2015-12-25 | 2017-07-04 | 沈阳中化农药化工研发有限公司 | A kind of reporting system for being applied to the type excretory system of plant pathogenetic bacteria III and its application |
CN110283843A (en) * | 2019-07-04 | 2019-09-27 | 西南大学 | A method of mediate CsWRKY22 fixed point editor to improve citrus bacterial canker disease resistance based on CRISPRCas9 |
CN114317584A (en) * | 2021-11-23 | 2022-04-12 | 海南医学院 | Construction system of novel transposon mutant library, novel transposon mutant library and application |
-
2023
- 2023-03-06 CN CN202310200163.3A patent/CN116042688B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000916A2 (en) * | 2000-06-28 | 2002-01-03 | California Institute Of Technology | Methods for identifying an essential gene in a prokaryotic microorganism |
CN101260399A (en) * | 2008-03-13 | 2008-09-10 | 邓子牛 | Anti-citrus canker pthA-nls gene and its construction method and application |
WO2011109031A1 (en) * | 2010-03-05 | 2011-09-09 | Synthetic Genomics, Inc. | Methods for cloning and manipulating genomes |
GB201322084D0 (en) * | 2013-12-13 | 2014-01-29 | Discuva Ltd | Method for identifying genes involved in antibiotic resistance and sensitivity in gram-negative bacteria |
WO2016180379A1 (en) * | 2015-05-14 | 2016-11-17 | Universidad De Los Andes | Novel transposon that promotes the functional expression of genes in episomal dna, and method for increasing dna transcription in the functional analysis of metagenomic libraries |
CN106916774A (en) * | 2015-12-25 | 2017-07-04 | 沈阳中化农药化工研发有限公司 | A kind of reporting system for being applied to the type excretory system of plant pathogenetic bacteria III and its application |
CN106086070A (en) * | 2016-06-07 | 2016-11-09 | 中山大学 | A kind of ProtoRAG Transposon System and application thereof |
CN106754606A (en) * | 2017-01-11 | 2017-05-31 | 中国农业科学院柑桔研究所 | The screening technique of the unmarked deletion mutant of citrus processing hfq genes |
CN110283843A (en) * | 2019-07-04 | 2019-09-27 | 西南大学 | A method of mediate CsWRKY22 fixed point editor to improve citrus bacterial canker disease resistance based on CRISPRCas9 |
CN114317584A (en) * | 2021-11-23 | 2022-04-12 | 海南医学院 | Construction system of novel transposon mutant library, novel transposon mutant library and application |
Non-Patent Citations (1)
Title |
---|
大豆斑疹病菌tal基因Tn5插入突变体的构建;黄坤炫;韩铖潇;谭棋仁;蔡璐璐;马文秀;邹丽芳;陈功友;;上海交通大学学报(农业科学版)(第02期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN116042688A (en) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11639511B2 (en) | CRISPR enabled multiplexed genome engineering | |
US20230383290A1 (en) | High-throughput precision genome editing | |
CN107474129B (en) | The method of specificity enhancing CRISPR-CAS system gene editorial efficiencies | |
ES2369859T3 (en) | PROCEDURE FOR CHROMOSOMIC INTEGRATION AND REPLACEMENT OF DNA SEQUENCE IN CLOSTRIDIA. | |
US20180127759A1 (en) | Dynamic genome engineering | |
WO2017083766A1 (en) | High-throughput crispr-based library screening | |
EP3940078A1 (en) | Off-target single nucleotide variants caused by single-base editing and high-specificity off-target-free single-base gene editing tool | |
WO2021083183A9 (en) | Hematopoietic stem cell hbb gene repair method and product | |
CN112430586B (en) | VI-B type CRISPR/Cas13 gene editing system and application thereof | |
CN116042688B (en) | Highly saturated transposon mutant library and construction method of X. citri | |
WO2023225358A1 (en) | Generation and tracking of cells with precise edits | |
CN113549650B (en) | CRISPR-SaCas9 gene editing system and application thereof | |
KR102421129B1 (en) | Novel protospacer adjacent motif sequence and method for modifying a target nucleic acid in the genome of a cell using the same | |
CN111254158A (en) | A method for eliminating drug-resistant plasmids in Enterobacteriaceae bacteria | |
Lyu et al. | Transferring functional chromosomes between intergeneric yeast generates monochromosomal hybrids with improved phenotypes and widespread transcriptional responses | |
CN115141817B (en) | A method and product for HBB gene repair in cells | |
CN117126818B (en) | Methods and applications of constructing gE gene-deleted PRV strains using ABE | |
CN101195830B (en) | Construction method for large fragment DNA clone carrier | |
CN107034232A (en) | Purposes of the ATG16L1 genes in the replication capacity of enhancing NDV | |
Li et al. | Inducible genome-wide mutagenesis for improvement of pDNA production by E. coli | |
WO2024093489A1 (en) | Control method for continuous evolution of eukaryotic cell and use thereof | |
Zheng et al. | Lambdoid phages with abundant Chi recombination hotspots reflect diverse viral strategies for recombination-dependent growth | |
CN116411003A (en) | Construction and application of endo-CRISPR-Cas system editing vector based on saccharopolyspora spinosa | |
CN118910116A (en) | Issatchenkia orientalis CRISPR/Cas9 gene editing system and application thereof | |
CN116814691A (en) | Methods to improve epi-BE4max-mediated editing efficiency of GDF9 gene target site |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |